What changed from existing technology?
Chemotherapy can make some leukemia cells stop dividing and become more visible to the immune system, which might help the body fight the cancer better.
This study is the first to show that chemotherapy can make leukemia cells more visible to the immune system by causing them to stop dividing and change their surface proteins.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
CD8+ T cell responses against AML, both ex vivo and in patient-derived xenograft models. TIS also restores AML sensitivity to immune checkpoint blockade ther
Abstract ↗emotherapy, but its immunological consequences in AML remain unclear. Here we show that ex vivo chemotherapy induces senescence in a subset of therapy-na
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding suggests that chemotherapy could be used in combination with immunotherapy to improve treatment outcomes for acute myeloid leukemia patients.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.